SUBSCRIBE: eNewsletter
A post-hoc analysis of Protocol T from the DRCR Retina Network, which compared anti-vascular endothelial growth factor (VEGF) compounds aflibercept, bevacizumab, and r
According to a 2018 American Eye-Q Survey conducted by the American
November is once again being recognized as Diabetic Eye Disease Awareness Month in an effort to educate the public on the effects of diabetes on vision, risk factors and treatment options.
At this year’s Retina Subspecialty Day during the American Academy of Ophthalmology (AAO), presentations as varied as
Treating diabetic retinopathy (DR) with anti-vascular endothelial growth factor (VEGF) agents is an alternative to panretinal laser, and in some studies it has been found that “
For patients with diabetic macular edema (DME), intravitreal anti-vascular endothelial growth factor (VEGF) agents have become the first-line treatment.
Anti-vascular endothelial growth factor (VEGF) therapy does not increase the risk of systemic serious adverse events in patients with diabetic macular edema (DME) compared with patients treated
The ASRS Global Trends Survey finds differences in some treatment preferences
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
